Clin2
NCT06845501Worth exploringRecruiting

Purine supplements for AICA-ribosiduria

AICA-ribosiduria Due to ATIC Deficiency

Part of Genetic & congenital, Hormones & metabolism clinical trials.

This trial tests whether adding purines (natural substances found in foods) to your diet can help treat AICA-ribosiduria, a rare genetic condition. It may be a safe and simple therapy option for you.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
10 people
Ages
3 years and older
Study type
Interventional

Who can take part

  • You must have a confirmed diagnosis of AICA-ribosiduria due to a problem with the ATIC enzyme.
  • You should not already be eating a diet high in purines (substances found in certain foods), as this could be a problem.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07750249Enrolling by invitation· Early Phase 1
Short-chain fatty acids for IgA nephropathy

This trial tests whether a daily supplement of short-chain fatty acids (SCFAs) can slow down kidney damage in people with IgA nephropathy. SCFAs are substances made by gut bacteria that may help reduce inflammation and protect the kidneys.

Martin
NCT06273644Recruiting
Carbohydrate-rich diet for acute intermittent porphyria

This trial tests whether a diet high in carbohydrates can help treat acute intermittent porphyria (AIP), a condition that can cause attacks of pain and other symptoms. If you have AIP, this study wants to see if eating more carbs can prevent or manage attacks.

Bodø, Nordland
NCT05755386Recruiting· Phase 3
Iptacopan for idiopathic IC-MPGN with heavy protein in urine

This trial tests iptacopan (an add-on medicine) in people with idiopathic immune-complex membranoproliferative glomerulonephritis (IC-MPGN), a kidney disease causing significant protein loss in urine. It aims to improve kidney outcomes and safety when added to standard treatments.

Los Angeles, California
NCT07530796Not yet recruiting· Phase 1/Phase 2
Gene Therapy for Aspartylglucosaminuria (AGU)

This trial tests a new gene therapy designed to treat aspartylglucosaminuria (AGU), a rare genetic disorder that affects how the body breaks down certain proteins. The therapy delivers a working copy of the AGA gene directly into cells to help the body function better.

NCT07125066Enrolling by invitation· Phase 1
Testing ACER-001 for combined D,L-2 hydroxyglutaric aciduria

This trial tests a drug called ACER-001 in a single patient with a rare metabolic disorder. The goal is to see if the drug helps manage symptoms.

Pittsburgh, Pennsylvania
NCT07182227Recruiting· Phase 1/Phase 2
Gene therapy PS-002 for IgA nephropathy

This trial tests a new gene therapy called PS-002 for adults with IgA nephropathy. It aims to see if the treatment is safe and can help reduce protein loss in urine and protect kidney function.

Miami, Florida

Hear when a new AICA-ribosiduria Due to ATIC Deficiency trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.